CSIMarket
 


Gilead Sciences Inc   (GILD)
Other Ticker:  
 
 

GILD's Operating Income Growth by Quarter and Year

Gilead Sciences Inc 's Operating Income results by quarter and year




GILD Operating Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 2,267.00 940.00 2,651.00
III Quarter September 2,623.00 2,837.00 3,842.00 2,001.00
II Quarter June 1,665.00 2,029.00 2,246.00 -2,983.00
I Quarter March 1,705.00 197.00 2,890.00 2,402.00
FY   5,993.00 7,330.00 9,918.00 4,071.00



GILD Operating Income third quarter 2023 Y/Y Growth Comment
Gilead Sciences Inc reported decrease in Operating Income in the third quarter 2023 by -7.54% to $ 2,623.00 millions, from the same quarter in 2022.
The decrease in the third quarter 2023 Gilead Sciences Inc 's Operating Income compares unfavorably to the Company's average Operating Income jump of 50.67%.

Looking into third quarter 2023 results within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Operating Income growth. While Gilead Sciences Inc ' s Operating Income decline of -7.54% ranks overall at the positon no. 937 in the third quarter 2023.

Explain Operating Income growth


GILD Operating Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - 141.17 % -64.54 % 142.54 %
III Quarter September -7.54 % -26.16 % 92 % -
II Quarter June -17.94 % -9.66 % - -
I Quarter March 765.48 % -93.18 % 20.32 % 7.38 %
FY   - -26.09 % 143.63 % -5.04 %

Financial Statements
Gilead Sciences Inc 's third quarter 2023 Operating Income $ 2,623.00 millions GILD's Income Statement
Gilead Sciences Inc 's third quarter 2022 Operating Income $ 2,837.00 millions Quarterly GILD's Income Statement
New: More GILD's historic Operating Income Growth >>


GILD Operating Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - -20.09 % -75.53 % 32.48 %
III Quarter September 57.54 % 39.82 % 71.06 % -
II Quarter June -2.35 % 929.95 % -22.28 % -
I Quarter March -24.79 % -79.04 % 9.02 % 119.76 %
FY (Year on Year)   - -26.09 % 143.63 % -5.04 %




Operating Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #4
Healthcare Sector #55
Overall #937

Operating Income Y/Y Growth Statistics
High Average Low
2464.91 % 50.67 % -168.29 %
(Sep. 30, 2008)   (Dec. 31, 2006)
Operating Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #4
Healthcare Sector #55
Overall #937
Operating Income Y/Y Growth Statistics
High Average Low
2464.91 % 50.67 % -168.29 %
(Sep. 30, 2008)   (Dec. 31, 2006)

Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Gilead Sciences Inc 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
929.95 % 20.98 % -84.25 %
(Jun 30 2022)  


GILD's III. Quarter Q/Q Operating Income Comment
Gilead Sciences Inc achieved in the III. Quarter 2023 above company average sequential Operating Income jump of 57.54%, to $ 2,623.00 millions, from $1,665.00 millions in the second quarter.
Biotechnology & Pharmaceuticals company is undergoing a remarkable growth, not only recording higher then regular increase, but also increasing pace.

Within Biotechnology & Pharmaceuticals industry Gilead Sciences Inc achieved highest sequential Operating Income growth. While Gilead Sciences Inc 's Operating Income growth quarter on quarter, overall rank is 175.


Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #1
Healthcare Sector #14
Overall #175
Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #1
Healthcare Sector #14
Overall #175
Operating Income Q/Q Growth Statistics
High Average Low
929.95 % 20.98 % -84.25 %
(Jun 30 2022)  


GILD's III. Quarter Q/Q Operating Income Comment
Gilead Sciences Inc achieved in the III. Quarter 2023 above company average sequential Operating Income jump of 57.54%, to $ 2,623.00 millions, from $1,665.00 millions in the second quarter.
Gilead Sciences Inc is undergoing a remarkable growth, with recording above regular gain, and additionally accelerating rate.

Within Biotechnology & Pharmaceuticals industry Gilead Sciences Inc achieved highest sequential Operating Income growth. While Gilead Sciences Inc 's Operating Income growth quarter on quarter, overall rank is 175.


Gilead Sciences Inc 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Operating Income 12 Months Ending $ 8,260.00 $ 8,474.00 $ 8,838.00 $ 7,330.00 $ 6,003.00
Y / Y Operating Income Growth (TTM) 37.6 % 20.92 % 22.33 % -26.09 % -48.38 %
Year on Year Operating Income Growth Overall Ranking # 1209 # 1472 # 313 # 121 # 1335
Seqeuential Operating Income Change (TTM) -2.53 % -4.12 % 20.57 % 22.11 % -14.34 %
Seq. Operating Income Growth (TTM) Overall Ranking # 937 # 1089 # 1393 # 1290 # 1414




Cumulative Operating Income growth Comment
Although Gilead Sciences Inc 's Annual Operating Income growth year on year were below company's average 50.67% , Operating Income announced in the Sep 30 2023 period, show improvement in Operating Income trend, to cumulative trailing twelve month growth of 37.6% year on year, from 20.92% in Jun 30 2023.

In the Healthcare sector 76 other companies have achieved higher trailing twelve month Operating Income growth. While Total ranking has impoved so far to 1209, from total ranking in previous quarter at 1472.

Operating Income TTM Q/Q Growth Statistics
High Average Low
2464.91 %
50.67 %
-168.29 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 4
Healthcare Sector # 77
Overall # 1209

Operating Income TTM Y/Y Growth Statistics
High Average Low
2464.91 %
50.67 %
-168.29 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 55
S&P 500 # 937
Cumulative Operating Income growth Comment
Although Gilead Sciences Inc 's Annual Operating Income growth year on year were below company's average 50.67% , Operating Income announced in the Sep 30 2023 period, show improvement in Operating Income trend, to cumulative trailing twelve month growth of 37.6% year on year, from 20.92% in Jun 30 2023.

In the Healthcare sector 76 other companies have achieved higher trailing twelve month Operating Income growth. While Total ranking has impoved so far to 1209, from total ranking in previous quarter at 1472.

Operating Income TTM Q/Q Growth Statistics
High Average Low
2464.91 %
50.67 %
-168.29 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 4
Healthcare Sector # 77
Overall # 1209

Operating Income TTM Y/Y Growth Statistics
High Average Low
2464.91 %
50.67 %
-168.29 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 55
S&P 500 # 937




Other Operating Income Growth
Biotechnology & Pharmaceuticals Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
GILD's Operating Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for GILD's Competitors
Operating Income Growth for Gilead Sciences Inc 's Suppliers
Operating Income Growth for GILD's Customers

You may also want to know
GILD's Annual Growth Rates GILD's Profitability Ratios GILD's Asset Turnover Ratio GILD's Dividend Growth
GILD's Roe GILD's Valuation Ratios GILD's Financial Strength Ratios GILD's Dividend Payout Ratio
GILD's Roa GILD's Inventory Turnover Ratio GILD's Growth Rates GILD's Dividend Comparisons



Companies with similar Operating Income jump for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Sep 30 2023
Bio techne Corp-0.81%$ -0.808 millions
The Pennant Group Inc -1.16%$ -1.162 millions
Bio rad Laboratories Inc -1.99%$ -1.990 millions
Corcept Therapeutics Inc-2.37%$ -2.371 millions
Mettler Toledo International Inc-3.07%$ -3.068 millions
Tenet Healthcare Corp-4.70%$ -4.698 millions
West Pharmaceutical Services Inc -4.78%$ -4.780 millions
Bruker Corporation-5.18%$ -5.179 millions
Henry Schein Inc -5.21%$ -5.213 millions
Hologic Inc-5.96%$ -5.962 millions
Sonida Senior Living Inc -6.27%$ -6.269 millions
Abbott Laboratories-6.95%$ -6.949 millions
Gilead Sciences Inc -7.54%$ -7.543 millions
Vertex Pharmaceuticals Inc-7.86%$ -7.864 millions
Bristol myers Squibb Company-9.18%$ -9.183 millions
Regeneron Pharmaceuticals Inc -9.21%$ -9.210 millions
National Research Corporation-10.39%$ -10.388 millions
Quest Diagnostics Inc-12.76%$ -12.755 millions
Bausch and Lomb Corp-13.04%$ -13.043 millions
Carlisle Companies Incorporated-13.87%$ -13.871 millions
Pediatrix Medical Group Inc -15.01%$ -15.015 millions
Community Health Systems Inc -15.20%$ -15.196 millions
Teva Pharmaceutical Industries Limited-15.27%$ -15.274 millions
Zynex inc -16.36%$ -16.362 millions
Entera Bio Ltd -16.72%$ -16.719 millions
Pacira Biosciences inc -16.76%$ -16.760 millions
Viatris Inc -19.35%$ -19.354 millions
Royalty Pharma Plc-21.21%$ -21.210 millions
Luna Innovations Inc-22.06%$ -22.057 millions
Avantor Inc -23.79%$ -23.785 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com